Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

Eligibility criteria:
Inclusion Criteria:

          -  Joined the study voluntarily and signed informed consent form

          -  Eastern Cooperative Oncology Group performance status of 0 to 1

          -  Life expectancy of more than 5 years

          -  Colorectal adenocarcinoma / mucinous adenocarcinoma / signet ring cell cancer
             confirmed by histopathology

          -  Stage T4NanyM0 cancer; or stage T3NanyM0 mucinous adenocarcinoma / signet ring cell
             cancer / adenocarcinoma with partly mucinous adenocarcinoma or signet ring cell cancer

          -  R0 resection of colorectal cancer

          -  Neutrophils (ANC) ≥ 1.5×10^9/L, Platelet count (Pt) ≥ 100× 10^9/L, Hemoglobin (Hb) ≥
             80 g/L, Hepatic function: ALT and AST ≤ 2.5 times upper limit of normal (ULN) and TBIL
             ≤ 1.5 times ULN, Renal function: creatinine ≤ 1.5 times ULN

          -  Use of an effective contraceptive for adults to prevent pregnancy

        Exclusion Criteria:

          -  Rectal cancer below peritoneal reflection (≤ 8cm above the anal verge)

          -  Other malignant tumors within the past 5 years, except for skin basal cell carcinoma,
             or cervical carcinoma in situ, who survived from radical treatment

          -  Severe adhesion of peritoneal cavity impossible to separate

          -  Abdominal infection

          -  Allergic to raltitrexed, 5-FU, and oxaliplatin; Dihydropyrimidine dehydrogenase (DPD)
             enzyme deficiency

          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior

          -  Drug addiction, Alcoholism or AIDS

          -  Impossible to tolerate the operation due to severe cardiac, lung, and vascular
             diseases

          -  Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 75 Years

Eligibility (NLI label): Entailment